- decreased bone mineral density / IMPC
- increased leukocyte cell number / IMPC
- decreased body length / IMPC
- abnormal coat/hair pigmentation / IMPC
- increased circulating alkaline phosphatase level / IMPC
- decreased lean body mass / IMPC
- decreased circulating glucose level / IMPC
- increased total body fat amount / IMPC
- decreased bone mineral content / IMPC
C57BL/6N-Baz2bem1(IMPC)Wtsi/WtsiCnbc
Status | Available to order |
EMMA ID | EM:13900 |
International strain name | C57BL/6N-Baz2bem1(IMPC)Wtsi/WtsiCnbc |
Alternative name | |
Strain type | Endonuclease-mediated |
Allele/Transgene symbol | Baz2bem1(IMPC)Wtsi |
Gene/Transgene symbol | Baz2b |
Information from provider
Provider | Wellcome Trust Sanger Institute |
Provider affiliation | Wellcome Trust Sanger Institute |
Genetic information | This mouse line originates from CRISPR zygote microinjection. For further details see the project page at the IMPC portal. |
Phenotypic information | Potential phenotyping data in the IMPC portal |
References | None available |
Information from EMMA
Archiving centre | CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain |
Animals used for archiving | heterozygous C57BL/6N |
Disease and phenotype information
IMPC phenotypes (allele matching)
IMPC phenotypes (gene matching)
- abnormal coat/hair pigmentation / IMPC
- decreased body length / IMPC
- decreased lean body mass / IMPC
- decreased bone mineral density / IMPC
- decreased bone mineral content / IMPC
- decreased circulating glucose level / IMPC
- increased circulating alkaline phosphatase level / IMPC
- increased total body fat amount / IMPC
- increased leukocyte cell number / IMPC
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).